Please assess the completion status of the following clinical trial:

Trial Title: Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion -~* Liver tumors treatable by SBRT not to exceed 10cm in greatest axial dimension.~  * 800 cc of uninvolved liver~ * Patients may have additional hepatic lesions if they are \<3cm and can be treated with TACE or RFA.~* Age \> 18 years old~* Albumin \> 2.4 g/dL.~* Total bilirubin \< 3 mg/dL.~* INR ≤ 1.5.~* Creatinine \< 2.0 mg/dL.~* Confirmed hepatocellular carcinoma by one of the following:~  * Histopathology~ * Two radiographic techniques (out of US, MRI, CT, Angiography) that confirm a lesion \>2 cm with arterial hypervascularization~ * One radiographic technique that confirms a lesion \>2 cm with arterial hypervascularization and an elevated AFP~* Hepatic lesion in patients for whom surgical resection is not possible or would not result in an opportunity for cure~* Tumor(s) \<10cm~* Eastern Clinical Oncology Group performance status 0, 1 or 2~* No prior surgery, chemotherapy, or radiation for the current tumor~* Patients placed on the liver transplant registry are eligible for this trial, but will be withdrawn from the protocol if they receive liver transplantation.~* TACE done prior to study enrollment is allowed if there were no more than 3 procedures within an 18 week period and SBRT can begin within 12 weeks of the last TACE procedure.~Exclusion -~* Prior radiotherapy to the upper abdomen~* Prior TACE, RFA, or liver transplant~* Tumor(s) ≥ 10cm~* Large esophageal varices without band ligation~* Active GI bleed or within 2 weeks of study enrollment~* Ascites refractory to medical therapy~* Contraindication to receiving radiotherapy~* Women who are pregnant~* Administration of any systemic cytotoxic agents within the last 12 months~* Presence of extrahepatic metastases~* Participation in another concurrent treatment protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stereotactic body radiotherapy (SBRT) (Type: EXPERIMENTAL): SBRT will be delivered on Varian's linear accelerator with On-Board Imaging (OBI) capabilities. The tumor will be tracked with the ethiodol material from the TACE procedure, and respiratory gating will be used to minimize motion due to respiration. Treatment will be given in either 3 or 5 fractions . SBRT will take place after the treatment planning and within 12 weeks of the last TACE procedure.~Doses: 45 Gy at 15 Gy/fraction , 36 Gy at 12 Gy/fraction, 45 Gy at 9 Gy/fraction, 40 Gy at 8 Gy/fraction

Based on this trial design, predict the completion outcome and termination type (if applicable).